Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed Ord Shs (NQ: AFMD )

1.200 -0.080 (-6.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,311,731
Open 1.280
Bid (Size) 1.200 (2)
Ask (Size) 1.240 (17)
Prev. Close 1.280
Today's Range 1.190 - 1.280
52wk Range 1.030 - 5.100
Shares Outstanding 123,419,772
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
From Affimed N.V.
Via Globe NewsWire
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
From Affimed N.V.
Via Globe NewsWire

Performance

YTD
-0.83%
-0.83%
1 Month
-0.83%
-0.83%
3 Month
-35.14%
-35.14%
6 Month
-63.30%
-63.30%
1 Year
-69.70%
-69.70%

More News

Read More
Dow Surges Over 250 Points; Weber Shares Spike Higher
Via Benzinga
Analyst Ratings for Affimed
Via Benzinga
4 Analysts Have This to Say About Affimed
Via Benzinga
Why Shares of Affimed Fell Thursday
Via The Motley Fool
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Analyst Says Affimed's 'Innate Cell Engagers Like No Others,' Sees Mammoth Upside
Via Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH
From Affimed N.V.
Via Globe NewsWire
US Stocks Higher; Dow Rises Over 100 Points
Via Benzinga
Citing Lack Of Durability, Affimed Scraps AFM13 Monotherapy Plans For NK Cell Combo
Via Benzinga
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
From Affimed N.V.
Via Globe NewsWire
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
From Affimed N.V.
Via Globe NewsWire
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
From Affimed N.V.
Via Globe NewsWire
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Lowe's, Alcon And Some Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
From Affimed N.V.
Via Globe NewsWire
Earnings Scheduled For November 15, 2022
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.